Startup profile · funding coverage
AstraNu funding, valuation and investors
Nokia Bell Labs photonics spinout building a compact swept-source optical coherence tomography imaging module for medical-device manufacturers.
Verified company research · funding, investors and latest developments
Keep track of AstraNu
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Seed
$3.5M · November 17, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$3.5M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
seed · Murray Hill, New Jersey, USA
Overview
AstraNu, spun out from Nokia Bell Labs in May 2025, manufactures a swept-source optical coherence tomography (SS-OCT) imaging engine for OEM device makers, rather than directly selling scanners to hospitals. OCT uses reflected light to construct high-resolution cross-sectional images.
AstraNu says its integrated photonics module is more than 10 times smaller than conventional swept-source systems and targets significantly lower system cost. Its first commercial focus is ophthalmology; ENT, urology and oncology integrations are exploratory. Its November 17, 2026 company-issued release confirms a $3.5M Seed led by Celesta Capital with a co-investment from the New Jersey Innovation Evergreen Fund through NJEDA.
Separate January or prior Celesta seed amounts are not disclosed. MobiHealthNews interviewed AstraNu's president, who said customer modules remain in joint development/testing and the team hopes for volume sales around mid-to-late 2027. This is not yet evidence of regulatory clearance, clinical outcomes, mass manufacturing, or booked revenue. Website names founders Michael Eggleston and Bibek Samanta; commercial lead Kevin Blalock.
Why AstraNu is interesting
$3.5M Seed funding supports partner validation and manufacturing preparation. The chip-scale imaging engine is not yet a widely shipped or independently clinically validated finished medical device.
Product & use cases
OEM adoption illustration (not hands-on testing): manufacturer identifies ophthalmic or ENT imaging requirements; asks AstraNu for optical-module specs and sample device; integrates laser, optics, signal processing and software into a larger instrument; validates imaging resolution, stability and thermal/mechanical reliability against existing OCT platform; performs safety/medical-device regulatory and clinical validation applicable to finished product; scales manufacturing only after acceptance. Manufacturer remains responsible for final device integration and clearance. Module price and guaranteed performance are not publicly disclosed.
- Integrate swept-source OCT into portable ophthalmology instruments where system size currently limits use.
- Explore portable ear, nose and throat imaging; earlier technology has been demonstrated in middle-ear imaging.
- Assess lower-footprint imaging modules for new OEM product designs, subject to device qualification.
Key facts
- $3.5M Seed led by Celesta Capital with New Jersey Innovation Evergreen Fund participation, announced November 17, 2026.
- Nokia Bell Labs spinout founded May 2025; chip-scale swept-source OCT is currently in partner validation.
- Volume module sales targeted for mid-to-late 2027, not established 2026 sales.
Funding history (newest first)
Seed
2026-11-17 $3.5M- Celesta Capital (lead)
- New Jersey Innovation Evergreen Fund (participant)
Source: Read source · prnewswire.com
Competitive landscape
Edge: Company claims integrated photonics reduce physical footprint and bill of materials while retaining swept-source performance, but independently audited system-level cost, reliability and image quality remain to be established.
Manufacturing yield, module optical performance across temperature, application integration, medical-device safety approvals, cost at scale, service/support economics and OEM customer acceptance remain open diligence points.
-
Conventional swept-source OCT component suppliers incumbent
Larger mature imaging engines with existing OEM integrations; cost/performance require verified comparisons.
-
Spectral-domain OCT solutions alternative
Established imaging technology with different scan-speed, depth and cost trade-offs.
-
Handheld ultrasound adjacent
Different imaging physics and clinical indications; cannot substitute for all OCT needs.
Market / IPO context
Editorial / static context — not a live quote.
FAQs about AstraNu
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.